Donna Kinzler, DNP, ACNP-BC, AOCNP, on HR+/HER2– Early Breast Cancer and Palbociclib Treatment

Donna Kinzler, DNP, ACNP-BC, AOCNP, of the Allegheny Health Network Cancer Institute, discusses phase III findings from the PALLAS study of interest to advanced practitioners. The trial showed that adding 2 years of palbociclib to ongoing adjuvant endocrine therapy did not improve survival for patients with stage II to III hormone receptor–positive and HER2-negative early breast cancer (Abstract GS1-07).